Iclusig 'partial hold' sends Ariad reeling; front-line CML at risk?
This article was originally published in Scrip
Executive Summary
Shares of Ariad Pharmaceuticals plummeted 76.6% in morning trading on 9 October on the company's disclosure of higher rates of serious arterial thrombosis in patients treated with the firm's leukemia drug Iclusig (ponatinib) than was previously seen at the medicine's accelerated approval last year – 11.8% at 24 months, versus 8% at 11 months.